Literature DB >> 12871139

Synthetic vaccines: the role of adjuvants in immune targeting.

Zi-Hua Jiang1, R Rao Koganty.   

Abstract

A clear understanding of the mechanism of function of immune stimulatory adjuvants, which commonly accompany vaccines, is beginning to emerge. Recent investigations have demonstrated that Toll-like receptors (TLRs) are the critical link between the innate and the adaptive immunity. This link, which is normally activated as a result of collaboration between adjuvants and TLRs in triggering adaptive immunity, has been a subject of several recent investigations. With the advent of well-defined synthetic small molecules, which are designed to either mimic the adjuvants or, as in many cases, to structurally represent pathogen associated molecular patterns, it is now possible to design reproducible experiments and to draw credible conclusions. An adjuvant alerts the host immune system through a mechanism similar to that of an infection by a pathogen, which involves interaction with a TLR followed by a lsqou;danger signal' to the immune system. Secretion of cytokines and regulation of the expression of co-stimulatory molecules induced by innate response shape the magnitude and quality of adaptive response. Synthetic vaccines containing specific epitopes to which immune responses are desired, are expected to be far superior in target specificity while the benefits may be long-lasting. The immune responses by therapeutic vaccines are generally adaptive in nature and such responses often require the participation of the components of innate immunity, most importantly the TLRs and their pathogen-associated binding compliments. Structurally well-defined synthetic molecules derived from lipid A, muramyl di-peptide (MDP), and CpG motifs from bacterial DNA offer a wide range of immune stimulants for the development of fully synthetic vaccines. Lipo-peptide and self-adjuvanted antigens, in combination with additional immune stimulatory adjuvants in liposome delivery system, may be important in vaccine design. Combinations of synthetic mimics of microbial products are known to display synergistic effects in stimulating the immune system. Either alone or in combination with chemotherapy, innate immune therapy using TLR ligands to stimulate the immune system may offer an alternate therapeutic approach against rapidly mutating viral infections-(HIV/AIDS), and cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871139     DOI: 10.2174/0929867033457340

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  16 in total

1.  The design and implementation of the immune epitope database and analysis resource.

Authors:  Bjoern Peters; John Sidney; Phil Bourne; Huynh-Hoa Bui; Soeren Buus; Grace Doh; Ward Fleri; Mitch Kronenberg; Ralph Kubo; Ole Lund; David Nemazee; Julia V Ponomarenko; Muthu Sathiamurthy; Stephen P Schoenberger; Scott Stewart; Pamela Surko; Scott Way; Steve Wilson; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-05-14       Impact factor: 2.846

Review 2.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

3.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines.

Authors:  Elena Y Enioutina; Diana Bareyan; Raymond A Daynes
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

5.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

6.  Robust immune responses elicited by a fully synthetic three-component vaccine.

Authors:  Sampat Ingale; Margreet A Wolfert; Jidnyasa Gaekwad; Therese Buskas; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2007-09-02       Impact factor: 15.040

7.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

8.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

9.  c-Jun N-terminal kinase 1 is required for Toll-like receptor 1 gene expression in macrophages.

Authors:  Hooman Izadi; Amirreza T Motameni; Tonya C Bates; Elias R Olivera; Vega Villar-Suarez; Ila Joshi; Renu Garg; Barbara A Osborne; Roger J Davis; Mercedes Rincón; Juan Anguita
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

Review 10.  Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines.

Authors:  Danica P Galonić; David Y Gin
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.